Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma

Dermatology

Volumn 219, Issue 1, 2009, Pages 7-21

  Schneeweiss, Sebastian ^a,b   Doherty, Mike ^b   Zhu, Shao ^b   Funch, Donnie ^b   Schlienger, Raymond G ^c   Fernandez Vidaurre, Carlos ^c   Seeger, John D ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b i3 Drug Safety   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic dermatitis; Drug safety; Lymphoma; Pimecrolimus; Tacrolimus; Topical corticosteroids

Indexed keywords

CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; INFANT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYMPHOMA; MALE; MIDDLE AGED; RISK FACTORS; TACROLIMUS; YOUNG ADULT;

EID: 67651112009     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209289     Document Type: Article

References (17)

1. Breuer K, Werfel T, Kapp A: Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005;6:65-77. (Pubitemid 40529749)
2. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006. (Pubitemid 30629127)
3. Won CH, Seo PG, Park YM, Yang JM, Lee KH, Sung KJ, Park CW, Kim DW, Chang HS, Won YH, Kim KH: A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatol Treat 2004;15:30-34. (Pubitemid 38252093)
4. FDA Public Health Advisory. www.fda.gov/cder/drug/advisory/elidel- protopic.htm (accessed January 22, 2008).
5. Langley RG, Luger TA, Cork MJ, Schneider D, Paul C: An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance. Dermatology 2007;215:27-44. (Pubitemid 350308378)
6. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127:808-816. (Pubitemid 46434650)
7. US National Psoriasis Foundation: Potencies of topical steroids. http://www.psoriasis.org/treatment/psoriasis/steroids/potency.php (accessed January 22, 2008).
8. Gu XS, Rosenbaum PR: Comparison of multivariate matching methods: structures, distances, and algorithms. J Comp Graphical Stat 1993;2:405-420.
9. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
10. Rothman KJ, Greenland S: Modern Epidemiology, ed 2. Philadelphia, Lippincott, Williams & Wilkins, 1998.
11. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
12. Hagstroemer L, Weimin Y, Nyren O, Emtestam L: Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 2005;141:1123-1127. (Pubitemid 41373958)
13. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH, Zheng T: Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-428. (Pubitemid 38988028)
14. Doody MM, Linet MS, Glass AG, Friedman GD, Pottern LM, Boice JD Jr, Fraumeni JF Jr: Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 1992;3:449-456.
15. Kelsey JL, Whittemore AS, Evans AS, Thompson WD: Methods in Observational Epidemiology, ed 2. New York, Oxford University Press, 1996, pp 341-390.
16. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 'negative' trials. N Engl J Med 1978;299:690-694.
17. Goodman SN, Berlin JA: The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994;121:200-206.